February is American Heart Month, and consumers should be aware that a high-sodium diet can increase their risk of developing high blood pressure. An estimated one in three Americans suffer from high blood pressure, which can increase the risk of developing cardiovascular disease – the leading cause of death in men and women in the United States.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65492-u-s-fda-reduce-sodium-intake-by-using-the-nutrition-facts-label
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their stories – from inspirational successes to daily struggles. Thousands of people from across the country responded, and revealed common challenges like eating healthy, exercising, sticking to a treatment plan and coping with the disease.
“Type 2 diabetes has affected my family, friends and fans, so I’ve learned it can be challenging to manage. It was great to hear from so many people, and I’m impressed by everyone’s dedication to their health,” said McGraw. “The stories we received shed an important light on the similar hardships people in the community face as they work toward achieving their blood sugar goals.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7988751-merck-americas-diabetes-challenge-tim-mcgraw-s-epatha-merkerson-chef-leticia-moreinos-schwartz/
Every three minutes someone in the U.S. is diagnosed with a blood cancer. No one knows this better than “Nashville” star Charles Esten and his wife Patty. Esten’s 15-year-old daughter, Addie, was diagnosed with leukemia at age 2 ½. Naturally, their world was turned upside down. But, they quickly learned that there was hope, based on research to advance new treatments and cures for leukemia, much of it funded by The Leukemia & Lymphoma Society (LLS).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7491051-charles-esten-light-the-night-walks/
Team In Training. Light The Night. Man & Woman of the Year. Student Series. Leukemia Cup Regatta. More than 13 million participants in these popular fundraising campaigns last year alone helped The Leukemia & Lymphoma Society (LLS) invest more than $1 billion in research to advance lifesaving treatments and cures for blood cancer patients.
For Blood Cancer Awareness Month this September, LLS is reminding us that despite progress, much work still needs to be done to save more lives. More than 1.2 million people in the U.S. are living with or in remission from a blood cancer. Leukemia causes more deaths than any other cancer among children, adolescents and adults younger than 20 years. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the U.S. in 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554853-lls-blood-cancer-awareness-month/
Today, VSP Vision Care, the largest not-for-profit vision benefits provider in the United States, and market research agency YouGov released new findings showing that half of people in the U.S. are neglecting their eyes despite 84 percent of people rating vision as their most important sense. This disconnect occurs because people don’t understand the importance of annual eye exams and its connection to overall health.
In fact, only 1 percent of people know that signs of serious conditions like thyroid disease, high blood pressure, autoimmune disorders and certain types of cancer can be detected through annual eye exams. This is concerning because even if you have naturally good vision and don’t need prescription glasses, you still need an annual eye exam to protect your overall health.
To view the multimedia release go to:
https://www.multivu.com/players/English/8363551-vsp-vision-care/
Hi there, I’m Rudy here to give you some information and tips on anemia. Just remember that you may be iron deficient and not know it. To find out, if you are, you will have to get a blood test. So, see your doctor if you feel you are deficient. Now let’s get started.
As sleaze oozes from the Pentagon,
banished Marine and Naval Academy alum Susanna Marcasi finds a web of
corruption and must take on a man to whom all are beholden, Defense
Secretary Manfred Stahl. Can she bring down the cloistered power
brokers deep within the military’s superstructure and survive? Blood
Stripe: The Susanna Marcasi Chronicles. Find out more at:
http://www.GinaMariaDiNicolo.com or on Amazon at:
http://j.mp/Blood-Stripe Cincinnati City Beat and
Amazon reviewer John Kelly says “Like a literary version of ‘A Few Good
Men (and Women)’ on steroids, Gina Maria DiNicolo rips into your
emotional core like a ‘kill shot’ from page one and never lets up for
322 pages. This book, not for the weak of heart, tells the story of
strength, courage and no mercy in the most elite units of the U.S.
Armed Forces.” Baltimore native Gina Maria DiNicolo graduated
from the U.S. Naval Academy with a degree in history and an attraction
to the unconventional. She accepted a commission in the U.S. Marine
Corps where she worked in aviation, recruiting, history, and public
affairs. As a fulltime author and historian, in addition to her two
books, DiNicolo has written scores of articles for the Military Officer
Magazine and other publications. After publishing Blood Stripe, she
sought to get her historian game on and accepted a one-year, work/study
assignment as a senior editor for the U.S. Army Center of Military
History in Washington, D.C., producing studies on military operations
in Iraq and Afghanistan. She is a dancer specializing in Argentine
Tango. For a review copy of Blood Stripe: The Susanna
Marcasi Chronicles or to arrange an interview with Gina Maria
DiNicolo contact Scott Lorenz of Westwind Communications Book
Marketing http://www.book-marketing-expert.com/ or by phone
734-667-2090.
